The Clinical and Endocrine Assessment of Three Different Antiandrogen Regimens Combined with a Very Long-Acting Gonadotrophin-Releasing Hormone Analogue

The current status of scientific research and hormonal treatments for carcinoma of the prostate

“…Their advantages are specificity and lack of cardiovascular toxicity (Waxman, 1987). The only side effect of treatment is tumour flare and this can be avoided by the concurrent use of antiandrogens (Waxman et al, 1988). Treatment was initially given as daily subcutaneous injections or five or six times daily nasal insufflations, but now is available as once monthly depot preparations.…”